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Objective: The regulation of bronchial epithelial TJs by TH2
cells and their cytokines and their involvement in epigenetic
regulation of barrier function were investigated.
Methods: The expression, regulation, and function of TJs were
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http://dx.doi.org/10.1016/j.jaci.2016.03.050Results: HBECs from asthmatic patients showed a significantly
low TJ integrity in ALI cultures compared with HBECs from
healthy subjects. TH2 cell numbers and levels of their cytokines,
IL-4 and IL-13, decreased barrier integrity in ALI cultures of
HBECs from control subjects but not in HBECs from asthmatic
patients. They induced a physical separation of the TJs of
adjacent cells in immunofluorescence staining of theTJmolecules
occludin and zonula occludens-1. We observed that expression of
histone deacetylases (HDACs) 1 and 9, and Silent information
regulator genes (sirtuins [SIRTs]) 6 and 7 were significantly high
in HBECs from asthmatic patients. IL-4 and IL-13 significantly
increased the expression of HDACs and SIRTs. The role of HDAC
activation on epithelial barrier leakinesswas confirmed byHDAC
inhibition, which improved barrier integrity through increased
synthesis of TJmolecules in epithelium fromasthmatic patients to
the level seen in HBECs from control subjects.
Conclusion: Our data demonstrate that barrier leakiness in
asthmatic patients is induced by TH2 cells, IL-4, and IL-13 and
HDAC activity. The inhibition of endogenous HDAC
activity reconstitutes defective barrier by increasing TJ
expression. (J Allergy Clin Immunol 2017;139:93-103.)
Key words: Asthma, bronchial epithelial cells, epigenetic, tight
junctions, TH2 cells, IL-4, IL-13, histone deacetylase
Asthma is a chronic inflammatory disorder of the airways
characterized by reversible obstruction.1,2 Type 2 inflammation,
with the major role of TH2 cells and their cytokines, is considered
a major pathophysiologic mechanism of asthma.3,4 TH2 cells pro-
duce a pattern of cytokines, such as IL-4, IL-5, and IL-13, which
cooperate in TH2 cell differentiation, IgE isotype switching and
production, tissue and blood eosinophilia, T-cell and eosinophil
homing to tissues, and airway hyperresponsiveness.4
Airway epithelial cells constitute the first-line barrier to
prevent penetration of environmental agents, such as allergens
and pollutants, into the inner tissues, and they mount an innate
immune response against infectious agents.5-7 The epithelial bar-
rier is predominantly formed by tight junctions (TJs) located at
the most apical part of the intracellular junctional complexes be-
tween the neighboring epithelial cells.8,9 They consist of trans-
membrane proteins: claudins, occludin, junctional adhesion
molecules, peripheral membrane proteins (eg, zonula occludens
[ZO-1, ZO-2, and ZO-3] and cingulin), and gap and adherens
junctions, which allow the transmembrane proteins to organize
in the membrane and attach to the cytoskeleton.8,9
The first observation of differences in TJ structures in asthmatic
patients was performed by using electron microscopy in 1988,
showing that varying degrees of TJ abnormalities were observed93
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subjects.10 Recent studies have shown that barrier function of the
epithelium is impaired in patients with various inflammatory dis-
eases, including asthma, atopic dermatitis, and chronic rhinosinu-
sitis.11-16 Disruption of bronchial epithelial TJ integrity leads to
loss of barrier function, enabling passage of proinflammatory
and tissue-damaging agents, such as allergens and toxins, from
the lumen into the airway parenchyma.17
Epigenetic changes are crucial for the development and
differentiation of various cell types and can regulate essential
genes, which are known to initiate and maintain asthmatic
inflammation.18-20 The mechanisms of epigenetic regulation
comprise the involvement of several families of enzymes, an um-
brella of biochemical reactions, such as chromatin modifications,
on histones and other structures and DNA methylation.21,22 The
balance between the actions of these enzymes is a very crucial
mechanism for the regulation of gene expression by controlling
numerous developmental processes and disease states.23,24
Increased expression of proinflammatory genes is regulated by
acetylation of core histones, particularly by histone acetyltrans-
ferases. In contrast, histone deacetylases (HDACs) remove the
acetyl groups from hyperacetylated histones, which leads to sup-
pression of gene transcription.25,26 They are classified in 5 groups:
class I includes HDACs 1, 2, 3, and 8; class IIa contains HDACs 4,
5, 7, and 9; class IIb consists of HDACs 6 and 10; class III com-
prises Silent information regulator genes (sirtuins [SIRTs]) 1 to 7;
and class IV includes only HDAC11.27,28
The aim of the present study was to investigate the regulation,
expression, and function of TJs of bronchial epithelial cells in
asthmatic patients in response to TH2 cells and their related cyto-
kines and those present in the epithelial cell microenvironment,
such as IL-4, IL-5, IL-13, IL-25, IL-33, and thymic stromal lym-
phopoietin (TSLP). We hypothesized that there is a relationship
between leakiness in the epithelium and increased activity of
HDACs in asthmatic patients. Our data demonstrated a mecha-
nism for leakiness in the epithelium in response to TH2 stimuli
and a novel role for IL-4 and IL-13 in increased HDAC expres-
sion. The inhibition of HDAC activity reconstitutes barrier integ-
rity in bronchial epithelial cells from asthmatic patients.METHODS
Study subjects
Bronchoscopy with epithelial cell brushings was performed in 27 subjects
(9 control subjects and 18 asthmatic patients). Clinical characteristics of thestudy participants are presented in Table E1 in this article’s Online Repository
at www.jacionline.org. Samples were collected at the University Hospital, Ja-
giellonian University Medical College, Krakow, Poland, and the University
Hospital Freiburg, Department of Pneumology, Freiburg, Germany. The diag-
nosis of asthma was mad by a pulmonologist or allergologist according to
Global Initiative for Asthma guidelines. All asthmatic patients and control
subjects were nonsmokers. The study was approved by the University
Bioethics Committee (KBET/209/B/2011), and the study subjects provided
written consent to participate.Air-liquid interface cultures
Primary human bronchial epithelial cells (HBECs) from bronchial brush-
ings of asthmatic patients and control subjects were grown in bronchial
epithelial basal medium (Lonza, Basel, Switzerland) supplemented with the
SingleQuot Kit placed in a 75-cm2 T-flask in a humidified incubator at 378C in
5% CO2. HBECs obtained from control subjects and asthmatic patients in
passages 2 or 3 were seeded in air-liquid interface (ALI) cultures onto 6.5-
mm-diameter polyester membranes with a pore size of 0.4 mm (growth
area, 0.33 cm2; Costar; Corning, Corning, NY) at a density of
1.5 3 105 cells/well. Bronchial epithelial growth medium (BEGM) supple-
mented with the SingleQuot kit, except for retinoic acid and triiodothyronine
(Lonza), was mixed 1:1 with Dulbecco modified Eagle medium (Gibco-BRL,
Invitrogen, Carlsbad, Calif). Fresh all-trans retinoic acid (Sigma-Aldrich,
Saint Louis, Mo) was supplemented at a concentration of 10 ng/mL, and me-
dium was changed every other day. Cells were grown submerged for 5 days to
complete confluence, apical medium was removed, and BEGM-DMEM at a
ratio of 1:1 with all-trans retinoic acid was added basolaterally to differentiate
these cells. Experiments were performed between 21 and 28 days of ALI cul-
ture. Six of 12 primary cell lines each for asthmatic patients and healthy con-
trol subjects were used for TH2 cells and ALI coculture experiments, and the
other 6 were used for stimulation with TH2-derived cytokines.
Cytokine stimulation and cocultures
ALI cultures were stimulated with different cytokines to the basolateral
compartment in the above-mentioned BEGM. IL-4 (Novartis, Basel,
Switzerland), IL-5 (PeproTech, Rocky Hill, NJ), IL-13 (eBioscience, San
Diego, Calif), IL-25, IL-33, and TSLP (R&D Systems, Minneapolis, Minn)
were all used at concentrations of 10 and 50 ng/mL. For the blocking
experiments, we used anti–IL-4 (2 mg/mL) and anti–IL-13 (3 mg/mL)
antibodies (both from R&D Systems) at the optimum dose, according to the
manufacturer’s instructions. These doses were sufficient to neutralize the
transepithelial electrical resistance (TER)–decreasing effect of exogenously
added IL-4 and IL-13 in ALI cultures of control HBECs. TH2 cells were
in vitro differentiated from naive T cells into TH2 cells, as described previ-
ously.29,30 BEGMwas mixed 1:1 with complete RPMI-1640 (Sigma-Aldrich)
containing 10% FCS and antibiotics for cocultured HBECs and TH2 cells.
HBECs were cocultured with TH2 cells at a concentration of 1 3 10
5 and
53 105 cells/well added to the basolateral compartment in the same total vol-
ume of 0.6 mL. TH2 cells were stimulated with anti-CD28 (125 ng/mL), anti-
CD3 (125 ng/mL), anti-CD2 (125 ng/mL), and IL-2 (100 U/mL). As a control,
epithelial cells alone were cultured by using the same conditions.Inhibition of HDACs
HBECs from control subjects and asthmatic patients cultured at the ALI
were treated with the HDAC inhibitor JNJ-26481585 (Apex Bio, Delhi, India)
diluted in BEGM-DMEM at different concentrations, including 5, 10, 50, and
100 nmol/L in the basolateral compartment.Transepithelial electric resistance and paracellular
flux measurement
TER of the HBECs grown in ALI cultures was measured daily by using the
Millicell ERS Voltohmmeter (Millipore, Temecula, Calif), and results were
presented as U3 cm2. Samples from each ALI culture donor were measured
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 1
WAWRZYNIAK ET AL 95in duplicates in multiple well systems. Paracellular flux across the epithelium
was measured when fluorescein isothiocyanate (FITC)–labeled 4-kDa dextran
(2 mg/mL, Sigma-Aldrich) was added apically. Two and 24 hours after addi-
tion, 2- and 24-hour paracellular flux experiments produced similar results.
FITC fluorescence in basolateral medium was assessed with a fluorescence
reader (Mithras LB 940; Berthold Technologies, Bad Wildbad, Germany) at
480 nm.mRNA isolation and RT-PCR
mRNA expression of bronchial epithelial cells of ALI cultures was
analyzed, as described earlier.12 TaqMan Low Density Array Micro Fluidic
Card PCR (Applied Biosystems, Foster City, Calif) was performed, as previ-
ously described.31 In the fluidic card PCR elongation factor 1awas used as the
housekeeping reference gene. The use of elongation factor 1a and glyceralde-
hyde-3-phosphate dehydrogenase as a control did not change the results.
Relative quantification was done on a ABI PRISM 7000 Sequence
Detection System (Applied Biosystems) with the 22DDCT formula, as
described previously.31Immunofluorescence staining of TJs
ALI cultures were fixed with 4% paraformaldehyde (Fluka/Sigma Aldrich,
Buch, Switzerland) at 48 or 72 hours, as described in the Results section. ALI
samples were blocked with goat serum in 1% BSA/PBS and stained for TJs:
occludin (mouse anti-occludin antibody, Alexa Fluor 488, 100 mg/mL,
Invitrogen); ZO-1 (rabbit, anti–ZO-1 unlabeled antibody, Invitrogen) detected
by using goat anti-rabbit antibody Alexa Fluor 546 or Alexa Fluor 633
(Invitrogen); claudin-4 (mouse anti-claudin-4 antibody, Invitrogen) detected
by using goat anti-mouse antibodyAlexa Fluor 546; E-cadherin (rabbit anti–e-
cadherin antibody, Alexa Fluor 555, Cell Signaling, Danvers, Mass); and
vimentin (monoclonal mouse anti-vimentin antibody; Dako, Glostrup,
Denmark) detected by using goat anti-mouse antibody Alexa Fluor 488
(Invitrogen). They were also stained for HDACs: HDAC1 (rabbit, polyclonal
anti-HDAC1 antibody; Abcam, Cambridge, United Kingdom); HDAC2
(mouse monoclonal anti-HDAC2 antibody, Abcam); HDAC7 (rabbit
polyclonal anti-HDAC7 antibody, Abcam); and HDAC9 (rabbit polyclonal
anti-HDAC9 antibody, Abcam). Finally, they were stained for SIRTs: SIRT1
(mouse monoclonal anti-SIRT1 antibody, Abcam); SIRT6 (mouse monoclonal
anti-SIRT6 antibody, Abcam) detected by using goat anti-mouse antibody
Alexa Fluor 488 (Invitrogen); and SIRT7 (rabbit polyclonal anti-SIRT7
antibody, Abcam) detected by using goat anti-rabbit antibody Alexa Fluor
546 (Invitrogen). Samples were mounted in the mounting medium ProLong
Gold with 49-6-diamisino-2-phenylindole dihydrochloride (DAPI; Life
Technologies, Grand Island, NY). Samples were analyzed with a Leica TCS
SPE confocal microscope (Leica Microsystems, Heerbrugg, Switzerland).
IMARIS software (Bitplane, Zurich, Switzerland) was used for 3-dimensional
visualization of TJs in HBECs and calculation of expression intensity.HDAC activity assay
HBECs from control and asthmatic donors were cultured in a 75-cm2 T-
flask or a 6-well plate, and after 7 days, the cells were collected and processed
according to the manufacturer’s instructions for the EpiQuik Nuclear Extrac-
tion Kit I (EpiGentek, Farmingdale, NY) and Epigenase HDAC Activity
Direct Assay Kit (colorimetric, EpiGentek). HDAC activity and the percent-
age of its inhibition was calculated, according to the manufacturer’s
instructions.Western blotting
Western blotting was performed, as previously described.32 Briefly,
equal amounts of lysate proteins (20 mg) were resolved on a 4-20%
Mini-PROTEAN TGX Gel (Bio-Rad Laboratories, Hercules, Calif) by using
103 Tris/glycine/SDS and deionized H2O running buffer (Bio-Rad Labora-
tories) and then transblotted to the nitrocellulose membranes by using the
Trans-Blot Turbo Blotting System (Bio-Rad Laboratories). The membraneswere blocked with 5% nonfat skimmed milk in PBS containing 0.1% Tween
20 for 1 hour and then incubated with the primary antibody overnight at
48C. Primary antibodies were the same as in immunofluorescence staining.
The membranes were subsequently washed and then incubated with a specific
secondary antibody conjugated with horseradish peroxidase (HRP) for 1 hour
(anti-rabbit HRP and anti-mouse HRP; Jackson ImmunoResearch Labora-
tories, West Grove, Pa). The blots were developed with the SuperSignal
West Femto Kit (Thermo Scientific, Waltham, Mass) and visualized on the
Luminescent Image Analyzer LAS-1000 (Fujifilm, Tokyo, Japan).
Statistical analysis
Data were analyzed with GraphPad Prism software (Version 5; GraphPad
Software, La Jolla, Calif). Differences between independent variables were
evaluated by using the Mann-Whitney U test. For differences between paired
values, the Wilcoxon rank sum test and 2-way ANOVAwere used. The results
were considered as significant at P values of less than .05, less than .01, less
than .001, and less than .0001.
RESULTS
Decreased bronchial epithelial cell TJ integrity in
asthmatic patients and the role of TH2 cells
We first investigated whether there was a difference in the TJ
barrier integrity of HBECs isolated from patients with asthma and
control subjects. The bronchial epithelial cells from asthmatic
patients showed a significantly lower TER compared with those
of control subjects during the first 7 days of development of ALI
cultures, as well as after long-term cultures (Fig 1, A and B).
Because asthma is a predominantly TH2 cytokine–dominated
disease, we then decided to coculture TH2 cells with HBECs to
investigate the effect of the TH2 cells. Control HBECs showed
decreased TER after 48 and 72 hours in an ALI cocultured with
TH2 cells. In contrast, ALI cultures of epithelium from asthmatic
patients had an initial low TER, which did not further decrease in
response to TH2 cells (Fig 1, C). Measurement of paracellular
passage of FITC-labeled 4-kDa dextran confirmed the link
between barrier integrity and TER results and was significantly
increased by TH2 cells in HBECs from control subjects (Fig 1,
D). TH2 cells cocultured with control HBECs showed separation
and opening of the TJs between neighboring cells, which
was illustrated in a video of immunofluorescence staining
(see Videos E1 and E2 in this article’s Online Repository at
www.jacionline.org). HBECs from asthmatic patients already
showed reduced expression of occludin and ZO-1 compared
with control subjects and did not respond to TH2 cells (Fig 1, E).
Next, we profiled the mRNA expression of the whole epithelial
junction–related complex (TJ molecules, adaptor proteins, gap,
and adherens junction) in ALI cultures of HBECs from asthmatic
patients and control subjects without any stimulation (see Fig E1
in this article’s Online Repository at www.jacionline.org). We
found that levels of claudin-4 and adaptor proteins and gap and
adherens junctions, such as plactoglobin, nectin-1, nectin-2, and
connexin-26, were expressed at significantly low levels in HBECs
from asthmatic patients compared with levels seen in control
epithelium.
IL-4 and IL-13 decrease the TJ integrity of bronchial
epithelial cells
During our investigations to identify the responsible factor of
TH2 cells that decreases barrier integrity, we demonstrated that
IL-4 and IL-13, the 2 main TH2 cytokines, induced a significant
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FIG 1. Barrier defect in ALI cultures of HBECs from asthmatic patients and their response to TH2 cells.A, TER
during development of ALI cultures from days 3 to 7 in HBECs from control subjects and asthmatic patients.
B, TER from HBECs after differentiation on day 21. C, TER in response to TH2 cells in ALI cultures of control
subjects and asthmatic patients. D, Paracellular flux of 4-kDa FITC-dextran in response to TH2 cells in ALI
cultures from control subjects and asthmatic patients. E, Representative immunofluorescence staining of
occludin and ZO-1 in ALI cocultured with TH2 cells (5 3 10
5 cells, 48 hours) in HBECs from control subjects
and ALI cultures of asthmatic patients. Arrows point out stratification of TJs. Data are presented as
means 6 SDs. *P < .05, **P < .01, and ***P < .001, Wilcoxon rank sum test. N 5 6 per group in duplicates.
u.s., Unstimulated.
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flux was significantly increased by IL-4 and IL-13 in parallel
cultures of healthy control cells, confirming the TER results
(Fig 2, B). The effects of IL-4 and IL-13 on TJs were also verified
by using immunofluorescence staining, as presented also in a
video, which demonstrated that ALI cultures displayed openings
of the TJs between neighboring cells (see Video E3 in this article’s
Online Repository at www.jacionline.org). There was already a
weak expression of occludin and ZO-1 in ALI cultures of HBECs
of asthmatic origin without any further change by IL-4 and IL-13
levels (Fig 2,C). Removal of IL-4 and IL-13 from culture leads to
recovery of TER in bronchial epithelial cells of control subjects(see Fig E2 in this article’s Online Repository at www.
jacionline.org). Blocking of IL-4 and IL-13 did not show any sig-
nificant difference in TER measurement in bronchial epithelial
cells from asthmatic patients (see Fig E3 in this article’s Online
Repository at www.jacionline.org). Other TH2 milieu cytokines,
such as IL-5, IL-25, IL-33, and TSLP, did not induce any change
in TER in HBECs of control subjects and asthmatic patients (see
Fig E4 in this article’s Online Repository at www.jacionline.org).
HDACs and SIRTs are upregulated by IL-4 and IL-13
It was tempting to investigate whether the barrier defect in
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FIG 2. Decreased epithelial barrier by IL-4 and IL-13 in ALI cultures. A, TER from IL-4 and IL-13 (50 ng/mL)–
stimulated HBECs from control subjects and asthmatic patients in ALI cultures. B, Paracellular flux of 4-kDa
FITC-dextran after stimulation with IL-4 and IL-13 (50 ng/mL) in HBECs from control subjects and asthmatic
patients. C, Representative immunofluorescence staining of occludin and ZO-1 in ALI cultures stimulated
with IL-4 and IL-13 (50 ng/mL, 48 hours) in control and asthmatic donors. Arrows point out stratification
of TJs. Data are presented as means 6 SDs. *P < .05, **P < .01, and ***P < .001, Wilcoxon rank sum test.
N 5 6 per group in duplicates. u.s., Unstimulated.
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Accordingly, HDAC expression in bronchial epithelial cells
showed potent regulation patterns in response to IL-4 and IL-
13. Most of the HDACs were significantly upregulated both in
control subjects and asthmatic patients on IL-4 and IL-13, which
was confirmed on mRNA (Fig 3, A) and protein (Fig 3, B) expres-
sion levels. After demonstration of their effects on HDACs, we
focused more on regulation of HDAC expression and activity in
the present study. Accordingly, we investigated the cellular local-
ization of HDACs and SIRTs in ALI cultures and observed that
HDAC1, HDAC2, SIRT1, SIRT6, and SIRT7 were localized in
the nucleus and HDAC7 and HDAC9 in the cytoplasm of HBECs
(see Fig E5, A, in this article’s Online Repository at www.
jacionline.org). As an important finding, higher mRNA expres-
sion of HDAC1 and HDAC9 was demonstrated in bronchial
epithelial cells from asthmatic donors compared with those
from control subjects (Fig 3, A, and see Fig E5, B). Western blot-
ting of the ALI cultures showed a significant increase in HDAC1
and HDAC2 protein expression in ALI cultures from control sub-
jects but not those from asthmatic patients, and HDAC7 expres-
sion was observed in epithelium from both control subjects and
asthmatic patients either by IL-4 or IL-13.Next, we investigated expression of the SIRT family of
HDACs, which are considered regulatory genes of different
biological functions, such as aging, metabolism, and stress
resistance.33 Similar to HDAC1 and HDAC9, higher expression
of SIRT6 and SIRT7 was found in resting conditions of HBECs
in asthmatic patients (see Figs E5 and E6 in this article’s Online
Repository at www.jacionline.org). SIRTs 1, 2, 4, 5, 6, and 7
were upregulated by IL-4 and IL-13. Additionally, expression
of SIRT1 and SIRT5 was significantly higher on IL-13 stimula-
tion in control subjects. These data demonstrate an essential
role for IL-4 and IL-13 in the regulation of the HDAC and
SIRT family of enzymes with epigenetic properties.Reconstitution of asthmatic bronchial epithelial
barrier integrity through HDAC inhibition
We analyzed further whether there is functional relevance of
increased mRNA and protein expression of HDACs in asthmatic
patients. As initial evidence suggesting this relationship, we
observed a significantly increased HDAC activity in bronchial
epithelial cells from asthmatic patients (Fig 4, A). This was fol-
















































































































































































































FIG 3. Increased expression of HDACs by IL-4 and IL-13. A, Expression of 11members of the HDAC family of
ALI cultures in HBECs from control subjects and asthmatic patients with IL-4 (50 ng/mL) and IL-13 (50 ng/mL)
for 48 hours. Measurement was performed with the TaqMan Micro Fluidic Card system. Data represent
means 6 SDs. *P < .05, **P < .01, ***P < .001, and ****P < .0001, Student t test. N 5 5 per group. u.s., Un-
stimulated. B, Representative Western blots of HDACs 1, 2, and 7 in HBECs from control subjects and asth-
matic patients after stimulation with IL-4 and IL-13 (n 5 3 per group).
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FIG 4. HDAC inhibition increased TJ expression in epithelial cells. A, HDAC activity in control and asthmatic
donors (n 5 4 per group). B, TER in ALI cultures of HBECs from control subjects and asthmatic patients
treated with 10 nmol/L HDAC inhibitor (JNJ-26481585). C, Fluorescence intensity for occludin and ZO-1
measured from immunofluorescence staining of HBECs from asthmatic patients treated with indicated
doses of JNJ-26481585 for 72 hours. D, Representative immunofluorescence staining of occludin and
ZO-1 in HBECs from asthmatic patients after treatment with HDAC inhibitor (Fig 4, C and D, n5 3 per group).
E, mRNA expression of occludin, ZO-1, claudin-7, and claudin-1 in ALI cultures of HBECs from control and
asthmatic donors after HDAC inhibition for 72 hours. Data represent means 6 SDs. *P < .05, **P < .01, and
***P < .001, 2-way ANOVA. N 5 8 per group. u.t., Untreated.
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tures were treated with a global HDAC inhibitor, JNJ-
26481585, to demonstrate the role of HDAC regulation through
the TH2 response on barrier function. The HDAC inhibitory activ-
ity of this compound was confirmed in epithelial cells in compar-
ison with another widely known HDAC inhibitor, trichostatin
A (see Fig E7 in this article’s Online Repository at www.
jacionline.org). HDAC inhibition significantly increased TER in
bronchial epithelial cells, particularly in ALI cultures from asth-
matic donors (Fig 4, B), but we did not observe any difference be-
tween patients with aspirin-tolerant asthma (ATA) and those with
aspirin-induced asthma (AIA; see Fig E8 in this article’s Online
Repository at www.jacionline.org). Reconstitution of TER in
ALI cultures from asthmatic patients was associated with an
increased expression of occludin and ZO-1 proteins with an intact
and honeycomb-like structure in a dose-dependent manner by us-
ing immunofluorescence staining (Fig 4, C and D).During recovery of epithelial barrier function through HDAC
inhibition, expression of E-cadherin (see Fig E9, A, in this arti-
cle’s Online Repository at www.jacionline.org), which plays a
role in cell binding and tissue formation, and the major interme-
diate filament-vimentin was also upregulated (see Fig E10, A, in
this article’s Online Repository at www.jacionline.org). In paral-
lel, expression of the TJs occludin, claudin-1, claudin-4,
claudin-7, and ZO-1 increased in a dose-dependent manner
through HDAC inhibition (Fig 4, E, and see Fig E9, B). In addi-
tion, genes, such as epidermal growth factor receptor, amphiregu-
lin, and Ki67, which are linked to the growth and regeneration of
epithelial cells, showed increased expression after HDAC inhibi-
tion, suggesting increased activation and proliferation of epithe-
lial cells (see Fig E10, B).
Then the question was posedwhether HDAC inhibition induces
stable barrier integrity in HBECs from asthmatic patients to
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FIG 5. HDAC inhibition protects bronchial epithelial cell barrier damage caused by IL-4 and IL-13. A, TER
HBECs from control subjects and asthmatic patients pretreated with 10 nmol/L HDAC inhibitor
(JNJ-26481585). After 72 hours of treatment, HDAC inhibitor was washed away, and all epithelial cells
were stimulated with IL-4 (50 ng/mL) and IL-13 (50 ng/mL) for 72 hours. TER measurement was performed.
Data represent means6 SDs. ***P < .001, 2-way ANOVA test. N5 3 per group. B, TERmeasurement of bron-
chial epithelial cells from control and asthmatic donors stimulated with IL-4 (10 ng/mL) and IL-13 (10 ng/mL)
and with the HDAC inhibitor JNJ-26481585 (100 nmol/L) for 72 hours (n 5 3). Data are presented as
means 6 SDs. *P < .05 and **P < .01, unpaired t test. N 5 3 per group. u.s., Unstimulated. C, TER measure-
ment of bronchial epithelial cells from control and asthmatic donors stimulatedwith IL-4 (10 ng/mL) and IL-13
(10 ng/mL) and together with the HDAC inhibitor JNJ-26481585 (100 nmol/L) for 72 hours (n 5 3). Data are
presented as means 6 SDs. *P < .05 and **P < .01, unpaired t test. N 5 3 per group. u.s., Unstimulated.
J ALLERGY CLIN IMMUNOL
JANUARY 2017
100 WAWRZYNIAK ET AL
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 1
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ALI cultures of HBECs from asthmatic patients (Fig 5). Normal
HBECs did not show any further increase. Afterward, the
HDAC inhibitor was washed away, and the ALI cultures were
stimulated with IL-4 and IL-13. Stimulation with these TH2 cyto-
kines significantly decreased TER in control epithelial cells, but
epithelial cells from asthmatic patients stayed at the same level
and did not decrease to initial low TER levels. Interestingly, the
initial effect of TER increase in epithelial cells of asthmatic pa-
tients after treatment with the HDAC inhibitor JNJ-26481585 re-
mained significantly high in the first 24 hours. Although statistical
significance disappeared after 48 and 72 hours, the IL-4 and IL-13
combination did not decrease TER fully to initial levels. These
data suggest that increased TER through HDAC inhibition is
partially sustained and cannot be rapidly and fully decreased by
TH2 cytokines. These data demonstrate that a protective effect
against TH2 cytokines is observed on the TJ barrier of asthmatic
epithelium by HDAC inhibition.
TER was decreased in epithelial cells from control subjects on
IL-4 or IL-13 stimulation, but this effect was reversed when
cytokines were added together with the HDAC inhibitor JNJ-
26481585. In contrast, IL-4 and IL-13 alone or in combination
with HDAC inhibition did not influence TER measurement in
epithelial cells form asthmatic patients.DISCUSSION
Although it is a heterogeneous disease with several phenotypes
and endotypes, the majority of asthma cases have been linked to
type 2 inflammation,34,35 with a strong evidence that TH2 cells can
initiate and maintain key pathophysiologic features through pro-
duction of cytokines, such as IL-4, IL-5, and IL-13.4,36 The barrier
integrity of bronchial epithelial cells is a very important compo-
nent of the defensemechanisms of the airways.17 Reduced epithe-
lial barrier function might increase the susceptibility to allergen
sensitization and decrease the threshold of exposure to a certain
allergen dose, which is required to drive local antigen-
dependent inflammation.37,38
Impairment of this protective function of TJs was suggested in
asthmatic patients as a potential causative factor in asthma
development. These studies were reviewed by Georas and
Rezaee.7 In some of these studies, the authors did not see any dif-
ferences in TER between asthmatic patients and nonasthmatic
subjects.39,40 The reasons for this discrepancy can be listed as a
growth factor dependency and the use of cadaveric samples. How-
ever, there is substantial evidence consistent with our data
showing reduced TER and decreased protein expression of TJs
(particularly, ZO-1 was analyzed) in asthmatic patients.16,41-43
These findings were not only confined to asthmatic patients
because irregular, patchy, and decreased expression of the TJ
molecules, occludin, and ZO-1 was described in the epithelial
layer of biopsy specimens of patients with chronic rhinosinusitis
with nasal polyps and patients with atopic dermatitis.11,31
Although TH2 cells and cytokines induced a gap between 2 adja-
cent epithelial cells, epithelium from asthmatic patients did not
typically show this gap. This difference can be due to chronic
inflammation and exposure to multiple inflammatory factors in
asthmatic patients and acute and short-term exposure to TH2 cells
and type 2 cytokines and remains to be further investigated. It can
be hypothesized that the cellular composition between ALI cul-
tures from asthmatic patients and control subjects might playrole in TER differences. However, it has been studied in detail
that ALI cultures from HBECs of healthy subjects and asthmatic
patients do not show any difference in cellular composition, such
as goblet cells and ciliated and nonciliated epithelial cells.39-41 In
addition, our experiments were performed in a group of patients,
including those with AIA, those with ATA, and control subjects.
Although AIA and ATA are suggested as different endotypes,
both groups show sputum eosinophilia,34 and our data demon-
strate that there is no difference in barrier leakiness.
The present study investigates the function and expression of
TJs in bronchial epithelial cells obtained from asthmatic patients
and control subjects and their link to the TH2 response and epige-
netic regulation. Our data suggest a mechanism for defective bar-
rier function in asthmatic patients, which was observed when
normal epithelial cells were exposed to cytokines produced by
effector TH2 cells. Epithelium from asthmatic patients showed
lower barrier integrity already at the start of ALI development,
as observed with low TERmeasurements. The protein expression
of TJs was significantly reduced and disassembled. In contrast,
the mRNA expression of TJs did not show any difference between
bronchial epithelial cells from asthmatic patients and control sub-
jects, which is in agreement with the findings of Xiao et al.41
To elucidate the mechanisms underlying the impaired integrity
of epithelium from asthmatic patients, we measured gene
expression of 62 TJs and associated proteins performed in ALI
cultures.31 It appeared that the mRNA expression of TJs, adaptor
proteins, and gap and adherens junctions, particularly claudin-4,
plactoglobin, nectin-1, nectin-2, and connexin-26, were ex-
pressed at low levels in asthmatic patients. Claudins 1, 4 and 7
have been reported to be the most expressed junctional molecules
in the lungs.41
Interestingly, the leaky barrier function of asthmatic epithelium
with decreased TER and increased paracellular flux in humanALI
cultures of bronchial epitheliumwas observed even after 2 to the 3
passages of the primary epithelial cells. These findings have led us
to investigate to role of epigenetics in barrier function and the
regulation of TJs in asthmatic patients. Here we demonstrate 2
essential findings of epigenetic regulation in asthmatic patients
showing that there is an increased gene expression of HDAC1 and
HDAC9 in asthmatic epithelium and that IL-4 and IL-13 are
potent upregulators of HDAC mRNA and protein expression. All
HDACs were upregulated by IL-4 and IL-13, except for HDAC1
and HDAC2 in asthmatic patients, suggesting that increased
HDAC activity is a hallmark of TH2-related asthma. Expression
of HDACs has been reported in several gene array studies, and
in one of them, HDAC1 and HDAC9 expression was upregulated
in bronchial epithelial cells of asthmatic patients similar to our
findings.44-46 Similar to our findings in asthmatic patients,
HDAC regulation has been reported with decreased expression
of HDACs 2, 3, 5, and 8 in peripheral lung tissue in comparison
with that seen in nonsmokers and in patients with different stages
of chronic obstructive pulmonary disease (COPD).47 In addition,
HDAC6-mediated selective autophagy was observed in patients
with COPD associated with cilia dysfunction.48
In agreement with the data for HDACs, SIRT expression
showed regulation patterns in response to IL-4 and IL-13 in
bronchial epithelial cells. These enzymes play an important role
in the cellular response to certain types of stress and toxicity. We
showed increased expression of SIRT6 and SIRT7 in asthmatic
patients. The regulation of SIRTs 2, 4, 6, and 7 showed a similar
response pattern to that of HDACs by IL-4 and IL-13 stimulation
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SIRT1 and SIRT5 were highly expressed after IL-13 stimulation
in bronchial epithelial cells from control subjects and also
together showed a stronger response to IL-13 compared with
that seen in asthmatic patients. It was also shown that filaggrin is
regulated by SIRT1, which is critical for skin barrier integrity.49
The SIRT family is involved in gene silencing, and several studies
have shown that expression of SIRT1, an anti-inflammatory and
antiaging protein, is decreased in the lungs of patients with
COPD. They also control the resistance to oxidative stress and
DNA repair.50 SIRT6 was associated with the redox state, in-
hibited cellular senescence and fibrosis, and was reported to
have protective effects against COPD.51
To complement the mRNA expression, we also observed
higher general activity of HDACs in bronchial epithelial cells
from asthmatic donors. The treatment of bronchial epithelial cells
of asthmatic patients with a new ‘‘second-generation’’ HDAC
inhibitor significantly increased barrier integrity, which can be
used for the prevention and treatment of asthma by correcting the
leaky epithelial barrier. This HDAC inhibitor, JNJ-26481585,
shows high potency for HDAC1; moderate potency for HDACs 2,
4, 10, and 11; and low potency to HDACs 6 and 7. It has greater
than 30-fold selectivity against HDACs 3, 5, 8, and 9.52,53 On
HDAC inhibition, increased mRNA and protein expression of
the junctional molecules occludin, ZO-1, claudin-4, claudin-7,
and E-cadherin, as well as improved TJ staining of epithelial cells,
which formed honeycomb-like structures, was observed in bron-
chial epithelial cells from both asthmatic patients and control sub-
jects. Together, these data suggest that chronic type 2 cytokine
exposure and increased HDAC activity might be one of the key
reasons for decreased barrier integrity in asthmatic patients.
HDAC inhibition was previously shown to lead to greater
expression of TJs, such as ZO-1, ZO-2, and cingulin, in fibroblasts
and Hela cell lines.54 It was also shown recently that CpG-DNA
can enhance the barrier function of bronchial epithelial cells in
asthmatic patients.55
Taken together, the present study showed decreased bronchial
epithelial barrier integrity in HBECs from asthmatic patients and
epigenetic regulation of the epithelial HDACs and SIRTs by IL-4
and IL-13, 2 of the most potent TH2 cytokines. The increased
expression of particular HDACs and SIRTs in asthmatic epithe-
lium, the correction of leakiness by inhibition of HDAC activity,
and the protective effect of HDAC inhibition on barrier integrity
opens a new window for the prevention and treatment of asthma.
Clinical implications: Decreased TJ integrity and altered bron-
chial epithelial barrier by TH2 cells and their cytokines in asth-
matic patients might play a role in increased exposure to
environmental factors, such as allergens, to the inner tissues
and contribute asthma pathogenesis.
REFERENCES
1. Akdis CA. Therapies for allergic inflammation: refining strategies to induce toler-
ance. Nat Med 2012;18:736-49.
2. Holtzman MJ. Asthma as a chronic disease of the innate and adaptive immune
systems responding to viruses and allergens. J Clin Invest 2012;122:2741-8.
3. Lambrecht BN, Hammad H. The immunology of asthma. Nat Immunol 2014;16:
45-56.
4. Fahy JV. Type 2 inflammation in asthma—present in most, absent in many. Nat
Rev Immunol 2015;15:57-65.
5. Rackley CR, Stripp BR. Building and maintaining the epithelium of the lung.
J Clin Invest 2012;122:2724-30.6. Holtzman MJ, Byers DE, Alexander-Brett J, Wang X. The role of airway epithe-
lial cells and innate immune cells in chronic respiratory disease. Nat Rev Immu-
nol 2014;14:686-98.
7. Georas SN, Rezaee F. Epithelial barrier function: at the front line of asthma
immunology and allergic airway inflammation. J Allergy Clin Immunol 2014;
134:509-20.
8. Kojima T, Go M, Takano K, Kurose M, Ohkuni T, Koizumi J, et al. Regulation of
tight junctions in upper airway epithelium. Biomed Res Int 2013;2013:947072.
9. Shen L. Tight junctions on the move: molecular mechanisms for epithelial barrier
regulation. Ann N Y Acad Sci 2012;1258:9-18.
10. Elia C, Bucca C, Rolla G, Scappaticci E, Cantino D. A freeze-fracture study of
human bronchial epithelium in normal, bronchitic and asthmatic subjects.
J Submicrosc Cytol Pathol 1988;20:509-17.
11. De Benedetto A, Rafaels NM, McGirt LY, Ivanov AI, Georas SN, Cheadle C,
et al. Tight junction defects in patients with atopic dermatitis. J Allergy Clin Im-
munol 2011;127:773-86, e1-7.
12. Soyka MB, Wawrzyniak P, Eiwegger T, Holzmann D, Treis A, Wanke K, et al.
Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junc-
tions by IFN-gamma and IL-4. J Allergy Clin Immunol 2012;130:1087-96.e10.
13. Kubo A, Nagao K, Amagai M. Epidermal barrier dysfunction and cutaneous
sensitization in atopic diseases. J Clin Invest 2012;122:440-7.
14. Yu HS, Kang MJ, Kwon JW, Lee SY, Lee E, Yang SI, et al. Claudin-1 polymor-
phism modifies the effect of mold exposure on the development of atopic derma-
titis and production of IgE. J Allergy Clin Immunol 2015;135:827-30.e5.
15. Elias PM, Wakefield JS. Mechanisms of abnormal lamellar body secretion and the
dysfunctional skin barrier in patients with atopic dermatitis. J Allergy Clin Immu-
nol 2014;134:781-91.e1.
16. de Boer WI, Sharma HS, Baelemans SM, Hoogsteden HC, Lambrecht BN,
Braunstahl GJ. Altered expression of epithelial junctional proteins in atopic
asthma: possible role in inflammation. Can J Physiol Pharmacol 2008;86:105-12.
17. Whitsett JA, Alenghat T. Respiratory epithelial cells orchestrate pulmonary innate
immunity. Nat Immunol 2015;16:27-35.
18. Issa JP. Aging and epigenetic drift: a vicious cycle. J Clin Invest 2014;124:24-9.
19. Alvarez-Errico D, Vento-Tormo R, Sieweke M, Ballestar E. Epigenetic control of
myeloid cell differentiation, identity and function. Nat Rev Immunol 2015;15:
7-17.
20. Yang IV, Schwartz DA. Epigenetic mechanisms and the development of asthma.
J Allergy Clin Immunol 2012;130:1243-55.
21. Comer BS, Ba M, Singer CA, Gerthoffer WT. Epigenetic targets for novel ther-
apies of lung diseases. Pharmacol Ther 2015;147C:91-110.
22. Mortaz E, Masjedi MR, Barnes PJ, Adcock IM. Epigenetics and chromatin re-
modeling play a role in lung disease. Tanaffos 2011;10:7-16.
23. Haberland M, Montgomery RL, Olson EN. The many roles of histone deacety-
lases in development and physiology: implications for disease and therapy. Nat
Rev Genet 2009;10:32-42.
24. Harb H, Renz H. Update on epigenetics in allergic disease. J Allergy Clin Immu-
nol 2015;135:15-24.
25. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al. Expression and
activity of histone deacetylases in human asthmatic airways. Am J Respir Crit
Care Med 2002;166:392-6.
26. Robert T, Vanoli F, Chiolo I, Shubassi G, Bernstein KA, Rothstein R, et al.
HDACs link the DNA damage response, processing of double-strand breaks
and autophagy. Nature 2011;471:74-9.
27. Livyatan I, Meshorer E. The HDAC interaction network. Mol Syst Biol 2013;9:
671.
28. Wang L, Liu Y, Han R, Beier UH, Bhatti TR, Akimova T, et al. FOXP31 regu-
latory T cell development and function require histone/protein deacetylase 3.
J Clin Invest 2015;125:1111-23.
29. Klunker S, Chong MM, Mantel PY, Palomares O, Bassin C, Ziegler M, et al.
Transcription factors RUNX1 and RUNX3 in the induction and suppressive func-
tion of Foxp31 inducible regulatory T cells. J Exp Med 2009;206:2701-15.
30. Meiler F, Zumkehr J, Klunker S, Ruckert B, Akdis CA, Akdis M. In vivo switch
to IL-10-secreting T regulatory cells in high dose allergen exposure. J Exp Med
2008;205:2887-98.
31. Kast JI, Wanke K, Soyka MB, Wawrzyniak P, Akdis D, Kingo K, et al. The broad
spectrum of interepithelial junctions in skin and lung. J Allergy Clin Immunol
2012;130:544-7.e4.
32. Sokolowska M, Chen LY, Liu Y, Martinez-Anton A, Qi HY, Logun C, et al. Pros-
taglandin E2 inhibits NLRP3 inflammasome activation through EP4 receptor and
intracellular cyclic AMP in human macrophages. J Immunol 2015;194:5472-87.
33. Hall JA, Dominy JE, Lee Y, Puigserver P. The sirtuin family’s role in aging and
age-associated pathologies. J Clin Invest 2013;123:973-9.
34. Wenzel SE. Asthma phenotypes: the evolution from clinical to molecular
approaches. Nat Med 2012;18:716-25.
J ALLERGY CLIN IMMUNOL
VOLUME 139, NUMBER 1
WAWRZYNIAK ET AL 10335. Akdis CA, Akdis M. Mechanisms of immune tolerance to allergens: role of IL-10
and Tregs. J Clin Invest 2014;124:4678-80.
36. Bird L. Regulatory T cells: CK2: keeping TH2 cells in check. Nat Rev Immunol
2015;15:134.
37. Schleimer RP, Kato A, Kern R, Kuperman D, Avila PC. Epithelium: at the inter-
face of innate and adaptive immune responses. J Allergy Clin Immunol 2007;120:
1279-84.
38. Lambrecht BN, Hammad H. Allergens and the airway epithelium response:
gateway to allergic sensitization. J Allergy Clin Immunol 2014;134:499-507.
39. Parker J, Sarlang S, Thavagnanam S, Williamson G, O’Donoghue D, Villenave R,
et al. A 3-D well-differentiated model of pediatric bronchial epithelium demon-
strates unstimulated morphological differences between asthmatic and nonasth-
matic cells. Pediatr Res 2010;67:17-22.
40. Hackett TL, Singhera GK, Shaheen F, Hayden P, Jackson GR, Hegele RG, et al.
Intrinsic phenotypic differences of asthmatic epithelium and its inflammatory re-
sponses to respiratory syncytial virus and air pollution. Am J Respir Cell Mol
Biol 2011;45:1090-100.
41. Xiao C, Puddicombe SM, Field S, Haywood J, Broughton-Head V, Puxeddu I,
et al. Defective epithelial barrier function in asthma. J Allergy Clin Immunol
2011;128:549-56, e1-12.
42. Post S, Nawijn MC, Jonker MR, Kliphuis N, van den Berge M, van Oosterhout
AJ, et al. House dust mite-induced calcium signaling instigates epithelial barrier
dysfunction and CCL20 production. Allergy 2013;68:1117-25.
43. Blume C, Swindle EJ, Dennison P, Jayasekera NP, Dudley S, Monk P, et al. Bar-
rier responses of human bronchial epithelial cells to grass pollen exposure. Eur
Respir J 2013;42:87-97.
44. Voraphani N, GladwinMT, Contreras AU, Kaminski N, Tedrow JR, Milosevic J, et al.
An airway epithelial iNOS-DUOX2-thyroid peroxidase metabolome drives Th1/Th2
nitrative stress in human severe asthma. Mucosal Immunol 2014;7:1175-85.
45. Kicic A, Hallstrand TS, Sutanto EN, Stevens PT, Kobor MS, Taplin C, et al.
Decreased fibronectin production significantly contributes to dysregulated repair
of asthmatic epithelium. Am J Respir Crit Care Med 2010;181:889-98.46. Bai J, Smock SL, Jackson GR Jr, MacIsaac KD, Huang Y, Mankus C, et al.
Phenotypic responses of differentiated asthmatic human airway epithelial cultures
to rhinovirus. PLoS One 2015;10:e0118286.
47. Ito K, Ito M, Elliott WM, Cosio B, Caramori G, Kon OM, et al. Decreased histone
deacetylase activity in chronic obstructive pulmonary disease. N Engl J Med
2005;352:1967-76.
48. Lam HC, Cloonan SM, Bhashyam AR, Haspel JA, Singh A, Sathirapongsasuti JF,
et al. Histone deacetylase 6-mediated selective autophagy regulates COPD-
associated cilia dysfunction. J Clin Invest 2013;123:5212-30.
49. Ming M, Zhao B, Shea CR, Shah P, Qiang L, White SR, et al. Loss of sirtuin 1
(SIRT1) disrupts skin barrier integrity and sensitizes mice to epicutaneous
allergen challenge. J Allergy Clin Immunol 2015;135:936-45.e4.
50. Shaw JG, Vaughan A, Dent AG, O’Hare PE, Goh F, Bowman RV, et al. Bio-
markers of progression of chronic obstructive pulmonary disease (COPD).
J Thorac Dis 2014;6:1532-47.
51. Chun P. Role of sirtuins in chronic obstructive pulmonary disease. Arch Pharm
Res 2015;38:1-10.
52. Arts J, King P, Marien A, Floren W, Belien A, Janssen L, et al. JNJ-
26481585, a novel ‘‘second-generation’’ oral histone deacetylase inhibitor,
shows broad-spectrum preclinical antitumoral activity. Clin Cancer Res
2009;15:6841-51.
53. Venugopal B, Baird R, Kristeleit RS, Plummer R, Cowan R, Stewart A,
et al. A phase I study of quisinostat (JNJ-26481585), an oral hydroxamate
histone deacetylase inhibitor with evidence of target modulation and anti-
tumor activity, in patients with advanced solid tumors. Clin Cancer Res
2013;19:4262-72.
54. Bordin M, D’Atri F, Guillemot L, Citi S. Histone deacetylase inhibitors up-
regulate the expression of tight junction proteins. Mol Cancer Res 2004;2:
692-701.
55. Kubo T, Wawrzyniak P, Morita H, Sugita K, Wanke K, Kast JI, et al. CpG-DNA
enhances the tight junction integrity of the bronchial epithelial cell barrier.
J Allergy Clin Immunol 2015;136:1413-6, e1-8.
